Cargando…
Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
Neurodegeneration in multiple sclerosis (MS) correlates with disease progression and reparative processes may be triggered. Growth-associated protein 43 (GAP-43) exhibits induced expression during axonal growth and reduced expression during MS progression. We aimed to evaluate if GAP-43 can serve as...
Autores principales: | Sandelius, Åsa, Sandgren, Sofia, Axelsson, Markus, Malmeström, Clas, Novakova, Lenka, Kostanjevecki, Vesna, Vandijck, Manu, Blennow, Kaj, Zetterberg, Henrik, Lycke, Jan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872811/ https://www.ncbi.nlm.nih.gov/pubmed/31754174 http://dx.doi.org/10.1038/s41598-019-54032-1 |
Ejemplares similares
-
Transient increase in CSF GAP-43 concentration after ischemic stroke
por: Sandelius, Åsa, et al.
Publicado: (2018) -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023) -
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023) -
Cerebrospinal fluid GAP-43 in early multiple sclerosis
por: Rot, U, et al.
Publicado: (2018) -
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)